Vertex Pharmaceuticals Incorporated (VRTX) earnings on May 4, 2026

After the market closes Q1 2026

More Vertex Pharmaceuticals Incorporated earnings

Prior outlook: Pessimistic Outcome: Accurate

The stock rose as much as 1.17% during the day after earnings were released, but closed 1.32% lower. The market response was negative despite the early gains.

VRTX price around the earnings

424.29

Change: -1.3%

2026-05-05, 19:59 UTC

Start of the measured window
412.60 419.89 427.17 434.46 429.98
Price series around the eventClosing price per minute from before the event to the end of the measured window.No trading (market closed)No trading (market closed)
May 4, 2026 May 5, 2026
  • Price: green if it ends above the starting price; red if it ends below
  • Start of the measured window
  • Market open
  • No trading (market closed)
  • Starting price
Price series around the event

Prior thesis

Prior outlook: Pessimistic Outcome: Accurate

Thesis published

Analysts positive, but caution is present due to the downtrend.

Experts are positive due to FDA approval and potential price increases, but the stock's recent downward trend makes them cautious about new investments.

Context analyzed before publication

Summary
Analysts are optimistic, noting the ongoing downtrend in recent sessions.
Reasoning
Experts are optimistic given the FDA approval and the current scenario, while noting the stock's recent downward trend.
Playbook
The recent price decline and the current risk/reward setup present a challenging scenario.
Trend
Outlook deteriorating over past five sessions.

Analysts

Drivers

  • Analysts Positive

    Analysts maintain ratings and cite price targets about the current stock price. Recent analyst actions, like target raises and upgrades, support an optimistic outlook.

Evidence

Analyst consensus
Buy
Consensus average (1-5)
1.61
Analysts covering the stock
29
Average price target
548.45
Lowest price target
330
Highest price target
641
Upside to price target
25.6%
Quarterly earnings growth
30.5%
Revenue growth
9.5%
Forward EPS
21.81
Trailing EPS
15.32
Analyst moves in the last 60 days
9
  • Strong buy: 5
  • Buy: 22
  • Hold: 4
  • Sell: 1
  • Strong sell: 1
Strong buy
5
Buy
22
Hold
4
Sell
1
Strong sell
1
  • April 10, 2026 · Morgan Stanley: Maintains rating (Overweight → Overweight)
  • March 18, 2026 · Maxim Group: Upgrades rating (Hold → Buy)
  • March 11, 2026 · Truist Securities: Maintains rating (Buy → Buy)
  • March 10, 2026 · Morgan Stanley: Maintains rating (Overweight → Overweight)
  • March 10, 2026 · B of A Securities: Maintains rating (Buy → Buy)
  • March 10, 2026 · Citigroup: Maintains rating (Buy → Buy)
  • March 10, 2026 · Oppenheimer: Maintains rating (Outperform → Outperform)
  • March 10, 2026 · Jefferies: Initiates coverage (Buy)
  • March 10, 2026 · HC Wainwright & Co.: Maintains rating (Buy → Buy)

News and sentiment

Drivers

  • News & sentiment Negative

    While the FDA approval is a notable event, the stock's subsequent decline suggests the market may have already factored in this news. High retail optimism with low market review volume could context a risk of crowded cases.

Evidence

Sentiment
Sentiment
Constructive
Mention volume
Low
Normalized volume
33%
News
Sources (6)
  • If You Invested $100 In Vertex Pharmaceuticals Stock 20 Years Ago, You Would Have This Much Today — Benzinga
  • Morgan Stanley Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $612 — Benzinga
  • The FDA Approves Expanded Use Of Vertex Pharmaceuticals' ALYFTREK (vanzacaftor/tezacaftor/ivacaftor) For Cystic Fibrosis In Patients 6 And Older — Benzinga
  • Vertex Pharmaceuticals Submits Povetacicept For The Treatment Of Immunoglobulin A Nephropathy For Accelerated Approval From The FDA; Expects FDA Review To Be Accelerated From Usual 10-Month Review Period To 6-Month Review — Benzinga
  • If You Invested $1000 In Vertex Pharmaceuticals Stock 15 Years Ago, You Would Have This Much Today — Benzinga
  • Watching Vertex Pharmaceuticals; Shares Trading Lower, FDA Label Update For ALYFTREK Adds Neuropsychiatric Risk Warning And Intracranial Hypertension, Alongside Strengthened Liver Safety Monitoring — Benzinga

Technicals

Drivers

  • Technical Negative

    The stock's recent performance is significantly weaker than the overall market, showing strong downward pressure. The current price is closer to resistance than to support.

Evidence

Average true range (ATR)
2.2%
Distance to 52-week high
-14.5%
14-day change (14d)
-2.4%
30-day change
-12.6%
30-day relative strength
-16.3%
Benchmark change
+3.8%
Nearest support
425.42
Nearest resistance
507.54
Volume accumulation ratio
0.72

Trends

Evidence

Average earnings surprise
-5.3%
  • February 12, 2026: actual EPS 4.65 vs estimate 4.58 (surprise +1.4%)
  • November 3, 2025: actual EPS 4.8 vs estimate 4.58 (surprise +4.9%)
  • August 4, 2025: actual EPS 4.52 vs estimate 4.25 (surprise +6.3%)
  • May 5, 2025: actual EPS 2.49 vs estimate 3.76 (surprise -33.7%)

Expected move

There is no implied-move data available for this event.

Reactions over its last 19 earnings

Median move
3.2%
75th percentile move
5.3%
90th percentile move
9%
Up / down moves
10 / 9
Average up move
+3.6%
Average down move
-5.7%

Monitoring and close

What Vertex Pharmaceuticals Incorporated reported

There is no monitoring data available for this event.

Pre-market second reading after the results

There is no second reading available for this event.

How the stock reacted

Outcome
Accurate
Consolidated
-1.3%
Max favorable move (MFE)
4%
Max adverse move (MAE)
1.2%